Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2017
June 2017, Vol 8, No 3
June 2017, Vol 8, No 3
Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management
By
Wayne Kuznar
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Enthusiasm for immunotherapy in the treatment of cancer must be balanced with a healthy respect for the power of T-cell activation. Autoimmunity is recognized as an effect of prolonged T-cell activation via PD-1/PD ligand 1 inhibition. Although immune-related adverse events are generally easily managed, they occasionally can be fatal and therefore should be managed without delay, said Stephanie Andrews, MS, ANP-BC, a hospitalist specializing in medical oncology at Moffitt Cancer Center, Tampa, FL, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference.
Read Article
Immune Stimulant Fails Randomized Test in Platinum-Resistant Ovarian Cancer
By
Charles Bankhead
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
National Harbor, MD—Platinum-resistant ovarian cancer also appeared resistant to the immunotherapeutic effects of the toll-like receptor 8 (TLR8) agonist motolimod as add-on to chemotherapy, according to results of a randomized trial.
Read Article
Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Washington, DC—Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab (Keytruda) led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, said lead investigator Yousef Zakharia, MD, Clinical Assistant Professor of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, at the 2017 American Association for Cancer Research meeting.
Read Article
Atezolizumab plus Bevacizumab Combo Shows Promise in Patients with Metastatic Kidney Cancer
By
Phoebe Starr
Immunotherapy
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Atezolizumab plus bevacizumab showed encouraging responses as a first-line treatment of metastatic renal-cell carcinoma in a phase 2 trial. Although the trial failed to meet its primary end point of significant improvement in progression-free survival (PFS) compared with sunitinib, the combination did reduce the risk for death or disease progression by 36% in patients with elevated PD ligand 1 (PD-L1) expression. The median PFS was almost double in the PD-L1–positive group with atezolizumab plus bevacizumab versus sunitinib (14.7 months vs 7.8 months, respectively).
Read Article
Updated NCCN Guideline for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
By
Wayne Kuznar
NCCN Conference Highlights
,
NCCN Guidelines
,
Policies & Guidelines
June 2017, Vol 8, No 3
Orlando, FL—Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression.
Read Article
NCCN Lung Cancer Guidelines: Combinations May Be the Future of Immunotherapy
By
Wayne Kuznar
Immunotherapy
,
NCCN Conference Highlights
,
Personalized Medicine
June 2017, Vol 8, No 3
Orlando, FL—Immunotherapy is now an established option for patients with non–small-cell lung cancer (NSCLC) in the second-line setting and in selected patients in the first-line setting.
Read Article
Multigene Panel Tests in Breast and Ovarian Cancers
NCCN Conference Highlights
June 2017, Vol 8, No 3
Orlando, FL—The National Comprehensive Cancer Network (NCCN) has provided guidance for the clinical management of genetic mutation carriers who are identified using multigene panels without endorsing the routine use of these tests outside of research and/or intensive counseling on the risks and benefits of their use.
Read Article
Clinical Pathways Cut Costs of Care in Non–Small-Cell Lung Cancer While Preserving Survival Rates
By
Wayne Kuznar
Value in Oncology
June 2017, Vol 8, No 3
Implementing clinical pathways for the management of patients with metastatic non–small-cell lung cancer (NSCLC) led to a dramatic reduction in the total cost of care, while maintaining clinical outcomes, according to a study of 370 patients with NSCLC conducted at Dana-Farber Cancer Institute in Boston.
Read Article
FDA News - June 2017
FDA Approvals, News & Updates
June 2017, Vol 8, No 3
A brief overview of cancer drugs approved by the FDA between March 15, 2017, and May 30, 2017.
Read Article
NCCN Recommends Biomarker Testing for All Patients with Newly Diagnosed NSCLC
By
Wayne Kuznar
NCCN Conference Highlights
June 2017, Vol 8, No 3
Orlando, FL—Molecular analysis and PD ligand 1 (PD-L1) testing for patients with non–small-cell lung cancer (NSCLC) are critically important. Optimally, multiple biomarker testing should be done at diagnosis, but it also has value before choosing therapy for second-line or later.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma